MedTrace Logo

Safety and Efficacy Study of IGF-1 in Duchenne Muscular Dystrophy

NCT01207908 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2021-01-20

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether IGF-1 therapy improves or preserves muscle function in Duchenne Muscular Dystrophy (DMD).

Conditions

Interventions

DRUG

IGF-1

IGF-1 will be administered once daily by subcutaneous injection every morning with breakfast. Duration 6 months.

Sponsors & Collaborators

  • Ipsen

    collaborator INDUSTRY

  • Charley's Fund

    collaborator OTHER

  • Children's Hospital Medical Center, Cincinnati

    lead OTHER

Principal Investigators

  • Meilan Rutter, MD · Children's Hospital Medical Center, Cincinnati

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
5 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2012-10-31
Completion
2013-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01207908 on ClinicalTrials.gov